AI risk programme and audited IT security, but evidence almost only for Health Answers
Overall rating “solid”. No deduction for controversies. The superscript numbers link directly to the source.
1 · Responsibility
Pfizer documents board oversight of AI risks and an AI risk programme under an AI Council, but publishes neither the policy nor an approval procedure.
What is documented
- The board's risk oversight names «cybersecurity and AI»; the Audit Committee oversees information security and technology risks1 2
- An AI risk management programme with principles, a group policy, training, risk review and controls sits under a cross-functional AI Council3
- The AI Council is co-chaired by the Chief AI and Analytics Officer, in office since 20244
- The code of conduct requires measures to assess and mitigate risks when developing, procuring and deploying AI6
- A Compliance Helpline is available around the clock and anonymously, with investigation by Compliance and a ban on retaliation6
The case against
No published operational AI rules
- The group AI policy, the approval process and a risk classification are not published
- There are no AI metrics such as an inventory, reviewed applications or training rate and no external audit or certification
Sources for Responsibility (11)
- Pfizer Inc. / U.S. Securities and Exchange Commission: Proxy Statement 2026 (Form DEF 14A) · 12 March 2026 · primary source
- Pfizer Inc. / U.S. Securities and Exchange Commission: Proxy Statement 2025 (Form DEF 14A) · 13 March 2025 · primary source
- Pfizer Inc.: Pfizer 2024 Impact Report · 31 December 2024 · primary source
- pharmaphorum: Pfizer grows digital team with chief AI officer appointment · 18 August 2024 · secondary source
- American Healthcare Leader: Pfizer AI (profile on AI compliance and generative AI) · 30 September 2024 · secondary source
- Pfizer Inc.: 2025 Blue Book: Pfizer's Code of Conduct · 1 January 2025 · primary source
- Pfizer Inc. (Global Policy & Public Affairs): Policy Position on Artificial Intelligence · 11 December 2023 · secondary source
- Pfizer Inc. (pfizer.com): Three Principles of Responsibility for Artificial Intelligence (AI) in Healthcare · 3 November 2026 · secondary source
- Digiday: With 'Charlie,' Pfizer is building a new generative AI platform for pharma marketing · 22 February 2024 · secondary source
- Pfizer Inc.: Pfizer 2025 Impact Report · 31 December 2025 · secondary source
- Pfizer Inc.: Human Rights Policy Statement (version of 28 May 2026) · 28 May 2026 · secondary source
2 · Safety
Pfizer describes in its 10-K a specific security programme audited by third parties, but AI-specific testing is documented only for Health Answers.
What is documented
- Item 1C describes NIST alignment, regular third-party assessments of maturity and the control environment, and internal and external penetration testing5 6
- Supplier risks, periodically tested incident response plans and Audit Committee oversight are documented5
- For Health Answers, independent physicians check articles and samples of AI answers against clinical guidelines; an independent advisory board reviews the guidelines1
- The Health Answers privacy policy excludes sale and sharing for behavioural advertising8
The case against
Missing evidence of AI testing
Sources for Safety (13)
- Pfizer Inc. (healthanswers.pfizer.com): Health Answers by Pfizer – How it Works · 3 November 2026 · primary source
- Digiday: With 'Charlie,' Pfizer is building a new generative AI platform for pharma marketing · 22 February 2024 · secondary source
- Amazon Web Services (AWS for Industries Blog): Three takeaways from Pfizer's AWS re:Invent keynote · 28 November 2023 · secondary source
- Pfizer Inc. (pfizer.com): AI in Drug Safety: Building the Elusive 'Loch Ness Monster' of Reporting Tools · 3 November 2026 · secondary source
- Pfizer Inc. / U.S. Securities and Exchange Commission: Form 10-K FY2025, XBRL R29: Cybersecurity Risk Management and Strategy Disclosure · 26 February 2026 · primary source
- Board Cybersecurity (board-cybersecurity.com): PFIZER INC 10-K Item 1C. Cybersecurity – 2026-02-26 · 26 February 2026 · secondary source
- Pfizer Inc.: Pfizer 2024 Impact Report · 31 December 2024 · primary source
- Pfizer Inc. (healthanswers.pfizer.com): Health Answers by Pfizer – Protecting your privacy (Privacy Policy) · 1 January 2025 · primary source
- Top Class Actions: Pfizer class action alleges website tracked users despite cookie opt-outs · 22 May 2026 · secondary source
- U.S. District Court S.D.N.Y. (via Leagle): Nakamura v. Pfizer Inc., Nos. 26-CV-3914 (JMF), 26-CV-5683 (JMF), Order · 23 July 2026 · primary source
- The HIPAA Journal: Cencora Cyberattack and Data Breach · 21 February 2024 · secondary source
- CyberMaterial: Pfizer Data Breach Affects Personal Info · 7 June 2024 · secondary source
- Board Cybersecurity (board-cybersecurity.com): PFIZER INC Cybersecurity Incident (Tracker) · 7 June 2024 · secondary source
3 · Transparency
For Health Answers Pfizer discloses the use of AI, sources, unverified answers and limits; for Charlie, VOX and research models, labelling and model information are missing.
What is documented
- Health Answers is labelled «powered by generative AI» and links the sources for each answer1 2
- Answers without independent sources are labelled «unverified»; Pfizer warns of hallucinations and incomplete answers1
- The Health Answers privacy policy discloses the use of AI with personal data3
- The source corpus of Health Answers is named, for example Harvard Health Publishing, CDC, FDA and NIH1
The case against
Only one product documented
Sources for Transparency (7)
- Pfizer Inc. (healthanswers.pfizer.com): Health Answers by Pfizer – How it Works · 3 November 2026 · primary source
- Pfizer Inc. (pfizer.com): Introducing Health Answers by Pfizer: New Consumer Digital Product Providing Answers · 3 November 2026 · secondary source
- Pfizer Inc. (healthanswers.pfizer.com): Health Answers by Pfizer – Protecting your privacy (Privacy Policy) · 1 January 2025 · primary source
- Pfizer Inc. / U.S. Securities and Exchange Commission: Form 10-K for the fiscal year ended December 31, 2025 · 26 February 2026 · primary source
- Pfizer Inc. (Global Policy & Public Affairs): Policy Position on Artificial Intelligence · 11 December 2023 · secondary source
- Pfizer Inc. (pfizer.com): Three Principles of Responsibility for Artificial Intelligence (AI) in Healthcare · 3 November 2026 · secondary source
- Pharmaceutical Technology (pharmaceutical-tech.com): Chai Discovery Signs Licensing Agreement with Pfizer to Advance AI-Driven Drug Discovery · 5 June 2026 · secondary source
4 · Why the harm rule does not apply
The harm rule does not apply: no AI-related harm, decision or settlement is documented within the window; the tracking lawsuit and the Cencora incident are unrelated to AI.
5 · Controversies (2)
- minorAccording to the Nakamura v. Pfizer class action, pfizer.com passed data to Google trackers despite «Decline All»; the proceedings are ongoing, a link to AI is not documented. · 22 May 2026 · open
- minorIn 2024 data from patient programmes of several drug companies, including Pfizer, was stolen at the service provider Cencora/The Lash Group; Cencora settled without admission of liability. · 21 February 2024 · Vergleich
6 · What remains open
- Wording of the AI risk factor in the FY2025 10-K, which was truncated on retrieval
- Current status and mandate of the AI Council and AI reporting to the board
- AI-specific metrics, validation results and external audits
- Model used and test results of Health Answers
- Labelling and review rules for AI-generated advertising content on the Charlie platform
- AI section «Responsible Technology» of the 2025 Impact Report
7 · How it was assessed
Cut-off date: 3 November 2026 · 41 searches, 35 fetches.
Primary documents read (10)
- Form 10-K FY2025 (cover page, forward-looking information, Item 1 incl. Data Privacy)
- Form 10-K FY2025 XBRL R29 (Item 1C Cybersecurity) and R25 (Contingencies, in part)
- Proxy Statements 2026, 2025 and 2024, and DEFA14A 2025
- Pfizer 2024 Impact Report (pp. 16, 23, 26, 27) and 2025 Impact Report (in part)
- Policy Position on Artificial Intelligence (December 2023)
- 2025 Blue Book (Code of Conduct)
- Human Rights Policy Statement (May 2026)
- Health Answers by Pfizer: How it Works and Privacy Policy
- DOJ press release on the Biohaven settlement (24 January 2025)
- Court order, Nakamura v. Pfizer (23 July 2026, via Leagle)
Research of 3 November 2026 under Globalance AI Footprint rulebook version 0